Valued Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Valued Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.5K	Buy	4 +1	+33%	+$681	﹤0.01%	622
2026 Q1	$2.32K	Buy	+3	New	+$2.3K	﹤0.01%	541
2025 Q2	–	Sell	-5	Closed	-$3.17K	–	643
2025 Q1	$3.17K	Sell	5 -7	-58%	-$4.82K	﹤0.01%	362
2024 Q4	$8.55K	Sell	12 -11	-48%	-$9.23K	0.01%	251
2024 Q3	$24.2K	Buy	23 +8	+53%	+$8.9K	0.02%	132
2024 Q2	$15.8K	Buy	15 +1	+7%	+$969	0.01%	151
2024 Q1	$13.5K	Buy	14 +6	+75%	+$5.71K	0.01%	156
2023 Q4	$6.58K	Buy	+8	New	+$6.59K	0.01%	166

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Valued Wealth Advisors's REGN Position: Q2 2026 in Review

Valued Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 33% in Q2 2026, buying an estimated $681 and bringing the position to 4 shares worth $2.5K. The position accounts for ﹤0.01% of the portfolio, ranked #622.

Valued Wealth Advisors first reported a position in REGN in Q4 2023 and has held it in 8 quarters since. The position peaked at $24.2K in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Valued Wealth Advisors held 4 shares of Regeneron Pharmaceuticals worth $2.5K as of Q2 2026.
Valued Wealth Advisors bought 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
Regeneron Pharmaceuticals made up ﹤0.01% of Valued Wealth Advisors's portfolio in Q2 2026, its #622 holding.
Valued Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Valued Wealth Advisors's Regeneron Pharmaceuticals position peaked at $24.2K in Q3 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Valued Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.